Tenascin-C is a large, multimodular, extracellular matrix glycoprotein that exhibits a very
restricted pattern of expression but an enormously diverse range of functions. Here, we …

Tenascin-C is an extracellular matrix glycoprotein that is specifically and transiently
expressed upon tissue injury. Upon tissue damage, tenascin-C plays a multitude of different …

The therapeutic utility of antibodies and their derivatives is achieved by various means. The
FDA has approved several targeted antibodies that disrupt signaling of various growth factor …

Antibody-cytokine fusion proteins (immunocytokine) exert a potent anti-cancer effect; indeed,
they target the immunosuppressive tumor microenvironment (TME) due to a specific anti …

Several cytokines have been investigated in clinical trials, based on their potent therapeutic
activity observed in animal models of cancer and other diseases. However, substantial …

Cytokines have long been used for therapeutic applications in cancer patients. Substantial
side effects and unfavorable pharmacokinetics limit their application and may prevent dose …

Antibody-cytokine fusion proteins represent a novel class of biopharmaceuticals, with the
potential to increase the therapeutic index of cytokine 'payloads' and to promote leukocyte …

Tenascin C (TNC), a glycoprotein that is abundant in the tumor extracellular matrix (ECM), is
strongly overexpressed in tumor tissues but virtually undetectable in most normal tissues …

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in
adults. Despite intensive treatment, the prognosis for patients with GBM remains grim with a …

Cytokines play a significant role in cancer diagnosis, prognosis and therapy. The immune
system's failure to recognize the malignant tumor cells and mount an effective response may …